William Mariner Greenman Sells 60,984 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS - Get Free Report) CEO William Mariner Greenman sold 60,984 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $91,476.00. Following the transaction, the chief executive officer now owns 4,309,758 shares of the company's stock, valued at $6,464,637. The trade was a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The stock was sold at an average price of $1.55, for a total transaction of $35,685.65.

Cerus Stock Performance

CERS traded down $0.03 during midday trading on Wednesday, hitting $1.47. 637,507 shares of the company traded hands, compared to its average volume of 1,302,988. The company's 50-day moving average is $1.73 and its 200 day moving average is $1.78. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $272.18 million, a PE ratio of -13.41 and a beta of 1.56. Cerus Co. has a 52 week low of $1.38 and a 52 week high of $2.54.

Cerus (NASDAQ:CERS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The company had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. On average, research analysts expect that Cerus Co. will post -0.08 EPS for the current year.

Remove Ads

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $4.00 price objective on shares of Cerus in a report on Friday, February 21st.

Institutional Trading of Cerus

A number of hedge funds have recently bought and sold shares of CERS. Rockport Wealth LLC bought a new stake in shares of Cerus during the 4th quarter valued at about $25,000. Cibc World Markets Corp purchased a new position in shares of Cerus in the fourth quarter worth approximately $26,000. R Squared Ltd bought a new stake in Cerus during the fourth quarter valued at approximately $29,000. Virtu Financial LLC purchased a new stake in Cerus during the fourth quarter valued at approximately $33,000. Finally, Dark Forest Capital Management LP bought a new position in Cerus in the fourth quarter worth approximately $34,000. Hedge funds and other institutional investors own 78.37% of the company's stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.